Orient Europharma Co. Ltd.

11/14/2024 | Press release | Distributed by Public on 11/14/2024 02:23

Announcement of the Board of Directors approved the consolidated financial reports of 2024Q3.

Close
Today's Information

Provided by: Orient Europharma Co., Ltd.
SEQ_NO 1 Date of announcement 2024/11/14 Time of announcement 16:21:43
Subject
 Announcement of the Board of Directors approved
the consolidated financial reports of 2024Q3.
Date of events 2024/11/14 To which item it meets paragraph 31
Statement
1.Date of the board of directors submitted or approved:2024/11/14
2.Date of the audit committee approved:2024/11/14
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2024/01/01 ~ 2024/09/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):3,257,533
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):1,543,924
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(9,966)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(27,462)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(106,477)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(149,032)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(1.72)
11.Total assets end of the period (thousand NTD):12,327,886
12.Total liabilities end of the period
(thousand NTD): 6,450,385
13.Equity attributable to owners of parent end of the
period (thousand NTD):5,221,181
14.Any other matters that need to be specified:None